Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Nov 21;3(11):1351–1366. doi: 10.1038/s43018-022-00456-0

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 4 — a, Mouse KP1 SCLC cells were engrafted into both flanks of B6129SF1 immunocompetent syngeneic mice and only right-side tumors were irradiated. b, Macrophages were depleted using an anti-CSF1 antibody, as quantified by flow cytometry (CD11b⁺F4/80⁺ cells) from the tumors of mice in the control group with or without anti-CSF1 antibody on day 17. n = 1 experiment with n = 5 mice (two tumors per mouse), P = 0.0010. c, Growth curves of KP1 SCLC allografts as in a,b with the indicated treatments. n = 1 experiment with n = 5 mice (two tumors per mouse). Irradiated tumors, **P = 0.0079, **P = 0.0011, **P = 0.0038; non-irradiated tumors, **P = 0.0079, **P = 0.0079. NS, not significant; Mac., macrophages. d, Uniform Manifold Approximation and Projection (UMAP) dimension 1 and 2 plots of viable CD45⁺ cells in non-irradiated KP1 tumors in NSG mice in the RT and RT/CD47-blockade treatment groups. Cell clusters are colored by cell populations. Colored arrows point to two groups of inflammatory macrophages whose numbers increase in non-irradiated tumors in the RT/CD47-blockade treatment group. e, Number of cells in each subpopulation identified in the scRNA-seq analysis in the two treatment groups. f, Human NCI-H82 cells stably expressing green fluorescent protein (GFP) were engrafted into both flanks of NSG mice and only right-side tumors were irradiated. g, Example of a flow cytometry analysis of CD11b⁺F4/80⁺ macrophages also positive for GFP (indicative of phagocytosis) in the two treatments were irradiated. Schematic of the depletion on CD11b⁺ cells. h, Quantification of g. Phagocytosis was measured 6 d after treatment start as the percentage of CD11b⁺F4/80⁺ macrophages that are also GFP⁺. n = 1 experiment with n = 6 mice. ****P < 0.0001. Two-tailed Student’s t-tests following two-way ANOVA were performed in c (irradiated tumors, P < 0.0001; non-irradiated tumors, P < 0.0001). Two-tailed Student’s t-tests were performed in b and h. Error bars represent s.e.m. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.

Source data